Industry News

AIM ImmunoTech announces first COVID-19-induced chronic fatigue ‘Long Hauler’ patient dosed with Ampligen

01/07/2021

Excerpt from the Article: AIM ImmunoTech Inc (NYSEAMERICAN:AIM) (FRA:HXB2) has announced Wednesday that the active AMP-511 Expanded Access Program (EAP) has dosed its first coronavirus (COVID-19) “Long Hauler” patient with the drug Ampligen (rintatolimod).  The company said the initial dosing marks a significant milestone in its efforts to develop an effective therapeutic for people suffering…

Read More

How mRNA went from a scientific backwater to a pandemic crusher

01/07/2021

Excerpt from the Article: In 1995, Katalin Karikó was at her lowest ebb. A biochemist at the University of Pennsylvania (UPenn), Karikó had dedicated much of the previous two decades to finding a way to turn one of the most fundamental building blocks of life, mRNA, into a whole new category of therapeutics. More often…

Read More

COVID-19 Can Cause Brain Damage Without Infiltrating Tissue

01/06/2021

Excerpt from the Article: COVID-19 is known to cause neurological complications in patients who test positive for the virus, but new research from the National Institutes of Health (NIH) has revealed that SARS-CoV-2 does not always find its way into the brains of infected patients. Based on findings from high-powered MRI scans, researches from the…

Read More

CHOP Researchers Receive Funding to Study Effects of COVID-19 on Preterm Birth

01/06/2021

Excerpt from the Press Release: Researchers at Children’s Hospital of Philadelphia (CHOP) have formed a new consortium that will study the effects of the COVID-19 pandemic on preterm birth and prenatal care, funded by $300,000 in grants from the Independence Blue Cross Foundation, Highmark Blue Cross Blue Shield Delaware’s donor-advised fund, and BluePrints for the…

Read More

New virtual screening strategy identifies existing drug that inhibits COVID-19 virus

01/05/2021

Excerpt from the Article: A novel computational drug screening strategy combined with lab experiments suggest that pralatrexate, a chemotherapy medication originally developed to treat lymphoma, could potentially be repurposed to treat Covid-19. Haiping Zhang of the Shenzhen Institutes of Advanced Technology in Shenzhen, China, and colleagues present these findings in the open-access journal PLOS Computational…

Read More

Study points the way to boost immunotherapy against breast cancer, other solid tumors

01/04/2021

Excerpt from the Article: Boosting immune system T cells to effectively attack solid tumors, such as breast cancers, can be done by adding a small molecule to a treatment procedure called chimeric antigen receptor-T (CAR-T) cell therapy, according to a study by researchers at the UNC Lineberger Comprehensive Cancer Center. The boost helps recruit more…

Read More

UCLH doses first patient in the world in Covid-19 antibody trial

01/01/2021

Excerpt from the Press Release: UCLH has opened a new vaccine research centre with two clinical trials testing a long-acting antibody combination treatment to protect against Covid-19. Researchers in the STORM CHASER study led by UCLH virologist Dr Catherine Houlihan have recruited the first participant in the world to the study. They believe the antibody…

Read More

Triple chemotherapy combination improves metastatic colorectal cancer outcomes

12/31/2020

Excerpt from the Press Release: Researchers from SWOG Cancer Research Network, a cancer clinical trials group funded by the National Cancer Institute (NCI), part of the National Institutes of Health, have shown that a triple drug combination – of irinotecan, cetuximab, and vemurafenib – is a more powerful tumor fighter and keeps people with metastatic…

Read More

Global trial reveals life saving drug for acute myeloid leukemia

12/30/2020

Excerpt from the Article: A landmark paper published today in the New England Journal of Medicine describes the results from a global trial across 148 sites in 23 countries, showing a 30 per cent improvement in survival in patients with acute myeloid leukemia (AML).  The Phase 3 clinical trial called QUAZAR, showed that a drug,…

Read More

AstraZeneca: Shot will be effective against COVID-19 variant

12/29/2020

Excerpt from the Article: The head of drugmaker AstraZeneca, which is developing a coronavirus vaccine widely expected to be approved by U.K. authorities this week, said Sunday that researchers believe the shot will be effective against a new variant of the virus driving a rapid surge in infections in Britain. AstraZeneca chief executive Pascal Soriot…

Read More